An article in last Tuesday’s HEALTHPlus, concerning drugs for melanoma sufferers, said wrongly that the drug Ipilimumab (Yervoy) had been turned down by the National Cancer Control Programme’s (NCCP) technology review group on cost grounds. In fact it was turned down by the National Centre for Pharmoeconomics (NCPE) and it is now being considered by the NCCP.
Bristol Myers Squibb, the manufacturer of the drug, has disputed the cost and says that the €85,000 per treatment figure provided by the NCPE is not the current cost under discussion with the HSE.
In An Irishwoman’s Diary in last Tuesday’s edition, it was stated that the concerts of music by Giovanni Gabrieli at City Hall in Dublin on February 4th, 11th and 18th would begin at 6.30pm. In fact the concerts begin at 6 pm.